Please wait a minute...
Journal of ZheJiang University(Medical Science)  2016, Vol. 45 Issue (1): 36-44    DOI: 10.3785/j.issn.1008-9292.2016.01.06
    
Update of pathological diagnosis of pulmonary neuroendocrine tumor
TENG Xiaodong1, ZHAO Ming2, LAI Maode3
1. Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;
2. Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China;
3. School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China
Download:   PDF(1224KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Pulmonary neuroendocrine tumors are common in pathological practice and its pathological classification and histological grading are not exactly the same as that of those in the digestive tract and pancreas. In 2015 edition of World Health Organization classification, pulmonary neuroendocrine tumors are classified as carcinoid tumors (including typical carcinoid and atypical carcinoid), small cell lung carcinoma, large cell neuroendocrine carcinoma, and precursor lesion diffuse idiopathic neuroendocrine cell hyperplasia; each category has distinctive morphological and immunohistochemical features. The morphologic features including growth patterns and cytological appearances are keys for the diagnosis of neuroendocrine tumor, and immunohistochemical findings are also critical for its diagnosis. Furthermore, the diagnostic criteria vary for different types of specimen. In this article, we present a concise review and summary of the update of clinicopathological characterizations of pulmonary neuroendocrine tumor, with an emphasis on its diagnostic criteria and differential diagnosis.



Key wordsCarcinoma, neuroendocrine/diagosis      Carcinoma, neuroendocrine/pathology      Lung neoplasms/diagnosis      Lung neoplasms/pathology      Small-cell lung carcinoma/pathology      Diagnosis, differential      Review     
Received: 20 December 2015     
CLC:  R73  
Cite this article:

TENG Xiaodong, ZHAO Ming, LAI Maode. Update of pathological diagnosis of pulmonary neuroendocrine tumor. Journal of ZheJiang University(Medical Science), 2016, 45(1): 36-44.

URL:

http://www.zjujournals.com/xueshu/med/10.3785/j.issn.1008-9292.2016.01.06     OR     http://www.zjujournals.com/xueshu/med/Y2016/V45/I1/36


肺神经内分泌肿瘤病理诊断进展

在临床诊断实践中肺神经内分泌肿瘤并不少见,其组织学分类、分级与消化道和胰腺神经内分泌肿瘤的分类分级标准并不完全相同。在2015年最新的WHO分类中,肺神经内分泌肿瘤分为类癌(包括典型类癌和不典型类癌)、小细胞肺癌、大细胞神经内分泌癌以及癌前病变——弥漫性特发性神经内分泌细胞增生等几个范畴,各自具有独特的形态学、免疫表型以及预后特征。神经内分泌肿瘤的诊断主要依据形态学的组织结构和细胞特征,免疫组织化学检测同样也起着重要的作用。此外,不同的标本类型中的诊断要点也明显不同。基于治疗和处理的不同,准确地诊断和鉴别诊断各范畴的肺神经内分泌肿瘤具有重要的临床意义。文中就肺神经内分泌肿瘤的临床病理进展作一简要总结, 着重强调其诊断和鉴别诊断要点。


关键词: 癌,神经内分泌/诊断,  癌,神经内分泌/病理学,  肺肿瘤/诊断,  肺肿瘤/病理学,  小细胞肺癌/病理学,  诊断,鉴别,  综述 
[[1]]   REKHTMAN N. Neuroendocrine tumors of the lung:an update[J]. Arch Pathol Lab Med, 2010, 134(11):1628-1638.
[[2]]   TRAVIS W D, BRAMBILLA E, NICHOLSON A G, et al. The 2015 World Health Organization classification of lung tumors:impact of genetic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol, 2015, 10(9):1243-1260.
[[3]]   TRAVIS W D, BRAMBILLA E, BURKE A P, et al. WHO classification of tumours of the lung, pleura, thymus and heart[M]. Lyon:International Agency of Research on Cancer, 2015:63-85.
[[4]]   TRAVIS W D. Advances in neuroendocrine lung tumors[J]. Ann Oncol, 2010, 21 Suppl 7(vii65-vii71).
[[5]]   LINNOILA R I. Functional facets of the pulmonary neuroendocrine system[J]. Lab Invest, 2006, 86(5):425-444.
[[6]]   GORSHTEIN A, GROSS D J, BARAK D, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors:clinical experience with a rare entity[J]. Cancer, 2012, 118(3):612-619.
[[7]]   AUBRY M C, THOMAS C F JR, JETT JR, et al. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens:analysis of 28 patients[J]. Chest, 2007, 131(6):1635-1643.
[[8]]   SWARTS D R, VAN SUYLEN R J, DEN BAKKER M A, et al. Interobserver variability for the WHO classification of pulmonary carcinoids[J]. Am J Surg Pathol, 2014, 38(10):1429-1436.
[[9]]   BEASLEY M B, THUNNISSEN F B, BRAMBILLA E, et al. Pulmonary atypical carcinoid:predictors of survival in 106 cases[J]. Hum Pathol, 2000, 31(10):1255-1265.
[[10]]   DU E Z, GOLDSTRAW P, ZACHARIAS J, et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids:TTF-1-positive carcinoids are predominantly in peripheral location[J]. Hum Pathol, 2004, 35(7):825-831.
[[11]]   GOSNEY J R, DENLEY H, RESL M. Sustentacular cells in pulmonary neuroendocrine tumours[J]. Histopathology, 1999, 34(3):211-215.
[[12]]   SICA G, WAGNER P L, ALTORKI N, et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors[J]. Arch Pathol Lab Med, 2008, 132(12):1889-1895.
[[13]]   PELOSI G, RINDI G, TRAVIS W D, et al. Ki-67 antigen in lung neuroendocrine tumors:unraveling a role in clinical practice[J]. J Thorac Oncol, 2014, 9(3):273-284.
[[14]]   FILOSSO P L, RENA O, GUERRERA F, et al. Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma:a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group[J]. Eur J Cardiothorac Surg, 2015, 48(1):55-64.
[[15]]   TRAVIS W D, RUSH W, FLIEDER D B, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid[J]. Am J Surg Pathol, 1998, 22(8):934-944.
[[16]]   TRAVIS W D. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas[J]. Mod Pathol, 2012, 25 Suppl 1:S18-S30.
[[17]]   NICHOLSON S A, BEASLEY M B, BRAMBILLA E, et al. Small cell lung carcinoma (SCLC):a clinicopathologic study of 100 cases with surgical specimens[J]. Am J Surg Pathol, 2002, 26(9):1184-1197.
[[18]]   SHIAO T H, CHANG Y L, YU C J, et al. Epidermal growth factor receptor mutations in small cell lung cancer:a brief report[J]. J Thorac Oncol, 2011, 6(1):195-198.
[[19]]   TRAVIS W D, BRAMBILLA E, MULLER-HERMELINK H K, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart[M]. Lyon:International Agency of Research on Cancer, 2004:44-52.
[[20]]   BARBARESCHI M, CANTALONI C, DEL VESCOVO V, et al. Heterogeneity of large cell carcinoma of the lung:an immunophenotypic and miRNA-based analysis[J]. Am J Clin Pathol, 2011, 136(5):773-782.
[[21]]   MASAI K, TSUTA K, KAWAGO M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas[J]. Appl Immunohistochem Mol Morphol, 2013, 21(4):292-297.
[[22]]   VERONESI G, MORANDI U, ALLOISIO M, et al. Large cell neuroendocrine carcinoma of the lung:a retrospective analysis of 144 surgical cases[J]. Lung Cancer, 2006, 53(1):111-115.
[1] GAO Siqian,SHEN Yongmei,GENG Funeng,Yanhua LI,Jianqing GAO. Temporal lobe epilepsy and adult hippocampal neurogenesis[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 97-105.
[2] WANG Ying,WANG Yi,CHEN Zhong. The role of central cholinergic system in epilepsy[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 15-21.
[3] GAO Siqian,SHEN Yongmei,GENG Funeng,LI Yanhua,GAO Jianqing. Research progress on the animal models and treatment strategies of diabetic foot ulcer[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 97-105.
[4] LI Wenlong,QU Haibin. Application progress on near infrared spectroscopy in quality control and process monitoring of traditional Chinese medicine[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 80-88.
[5] ZHENG Yanrong,ZHANG Xiangnan,CHEN Zhong. Research progress on mechanism of Nix-mediated mitophagy[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 92-96.
[6] FENG Sheng, CHEN Jijun, ZHENG Yichun. Research progress on the effect of glucocorticoid receptor signaling pathways in bladder cancer[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 655-660.
[7] LI Tongyu, LIANG Ping. Research progress on disease models and gene therapy of Duchenne muscular dystrophy[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 648-654.
[8] CAO Peng, LENG Dongjin, LI Ying, ZHANG Ziwei, LIU Lei, LI Xiaoyan. Progress on anti-tumor molecular mechanisms of dihydroartemisinin[J]. Journal of ZheJiang University(Medical Science), 2016, 45(5): 501-507.
[9] LI Tingting, KE Yuehai, CHENG Hongqiang. Reasearch progress on the role of neutrophils in asthma[J]. Journal of ZheJiang University(Medical Science), 2016, 45(5): 544-549.
[10] WANG Xue, ZHANG Yuchuan, CHEN Wei. Research progress on the role of TANK-binding kinase 1 in anti-virus innate immune response[J]. Journal of ZheJiang University(Medical Science), 2016, 45(5): 550-557.
[11] DU Miaomiao, MA Gaigai, SHI Yuping. Research progress on pharmacotherapy of calcific aortic valve disease[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 432-438.
[12] HE Bin, CHAI Yanlan, WANG Tao, ZHOU Zhenxing, LIU Zi. Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 395-402.
[13] LI Xueying, ZHU Lixia, YE Xiujin. Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 387-394.
[14] ZHU Tianhong, ZHANG Xinmei. Research progress on the role of epithelial-mesenchymal transition in pathogenesis of endometriosis[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 439-445.
[15] XU Yulan, XUE Yadan, KANG Lijun. The effect of glial cells in the function and development of the nervous system in Caenorhabditis elegans[J]. Journal of ZheJiang University(Medical Science), 2016, 45(3): 315-322.